Research progress of nicorandil in prevention of contrast agent-related acute renal injury in patients with coronary intervention

VernacularTitle:尼可地尔预防经皮冠状动脉介入治疗患者造影剂相关急性肾损伤的研究进展
Author: Wenjian XU ¹ ; Minqi LIAO ; Yongzhao YAO ; Suxia GUO
Author Information

1. 广东医科大学，湛江　524023
Keywords: Contrast-associated acute kidney injury; Percutaneous coronary intervention; Nicorandil; Prevention
From: Clinical Medicine of China 2023;39(2):140-144
CountryChina
Language:Chinese
Abstract: With the rapid development of imaging and percutaneous coronary intervention, the application of contrast media has become more and more widespread, and contrast-associated AKI has become one of the most common causes of acute kidney injury. Contrast-associated AKI seriously threatens patients' health and brings greater economic burden to patients, so it is particularly important to prevent the contrast-associated AKI. Nicorandil is a common vasodilator drug in clinical practice, widely used in the treatment of angina pectoris, with the effects of anti-oxidative stress, anti-apoptosis, anti-inflammatory and vasodilation, and is considered to be effective in preventing contrast - associated AKI. However, there is still a lack of further research on the efficacy of nicorandil in preventing contrast-associated AKI.